Ming H Hsieh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4112555/publications.pdf

Version: 2024-02-01

201674 182427 3,054 109 27 51 citations h-index g-index papers 113 113 113 4547 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients. Biological Psychiatry, 2006, 60, 1231-1240.	1.3	384
2	Startle Gating Deficits in a Large Cohort of Patients With Schizophrenia. Archives of General Psychiatry, 2006, 63, 1325-35.	12.3	305
3	MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia. PLoS ONE, 2011, 6, e21635.	2.5	200
4	Frequencyâ€specific alternations in the amplitude of lowâ€frequency fluctuations in schizophrenia. Human Brain Mapping, 2014, 35, 627-637.	3.6	197
5	Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia. PLoS ONE, 2013, 8, e57516.	2.5	74
6	A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention. Biological Psychiatry, 2006, 60, 554-562.	1.3	64
7	Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. Translational Psychiatry, 2016, 6, e717-e717.	4.8	64
8	Auditory event-related potential of subjects with suspected pre-psychotic state and firstâ€episode psychosis. Schizophrenia Research, 2012, 140, 243-249.	2.0	61
9	More evidence supports the association of PPP3CC with schizophrenia. Molecular Psychiatry, 2007, 12, 966-974.	7.9	57
10	Automatic whole brain tractâ€based analysis using predefined tracts in a diffusion spectrum imaging template and an accurate registration strategy. Human Brain Mapping, 2015, 36, 3441-3458.	3.6	55
11	Mismatch negativity to different deviant changes in autism spectrum disorders: A meta-analysis. Clinical Neurophysiology, 2020, 131, 766-777.	1.5	52
12	RASD2, MYH9, and CACNG2 Genes at Chromosome 22q12 Associated with the Subgroup of Schizophrenia with Non-Deficit in Sustained Attention and Executive Function. Biological Psychiatry, 2008, 64, 789-796.	1.3	51
13	Memory impairment and auditory evoked potential gating deficit in schizophrenia. Psychiatry Research - Neuroimaging, 2004, 130, 161-169.	1.8	49
14	No association of G72 and d-amino acid oxidase genes with schizophrenia. Schizophrenia Research, 2006, 87, 15-20.	2.0	49
15	Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia. PLoS ONE, 2013, 8, e66571.	2.5	45
16	Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology, 2015, 53, 1-9.	2.7	44
17	More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones. Schizophrenia Research, 2006, 87, 172-180.	2.0	40
18	P50, N100, and P200 Auditory Sensory Gating Deficits in Schizophrenia Patients. Frontiers in Psychiatry, 2020, 11, 868.	2.6	40

#	Article	IF	CITATIONS
19	Haplotypes of the D-Amino Acid Oxidase Gene Are Significantly Associated with Schizophrenia and Its Neurocognitive Deficits. PLoS ONE, 2016, 11, e0150435.	2.5	38
20	Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading. Schizophrenia Bulletin, 2009, 35, 213-221.	4.3	35
21	Clustering by neurocognition for fine mapping of the schizophrenia susceptibility loci on chromosome 6p. Genes, Brain and Behavior, 2009, 8, 785-794.	2.2	34
22	Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests. PLoS ONE, 2012, 7, e34454.	2.5	34
23	Effects of Background and Prepulse Characteristics on Prepulse Inhibition and Facilitation: Implications for Neuropsychiatric Research. Biological Psychiatry, 2006, 59, 555-559.	1.3	33
24	Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population. Psychiatric Genetics, 2006, 16, 39-41.	1.1	33
25	Polygenic risk for schizophrenia and neurocognitive performance in patients with schizophrenia. Genes, Brain and Behavior, 2018, 17, 49-55.	2.2	33
26	Familial Aggregation in Skin Flush Response to Niacin Patch Among Schizophrenic Patients and Their Nonpsychotic Relatives. Schizophrenia Bulletin, 2006, 33, 174-182.	4.3	32
27	Follow-up of subjects with suspected pre-psychotic state in Taiwan. Schizophrenia Research, 2011, 126, 65-70.	2.0	30
28	Performance on the Wisconsin Card Sorting Test in Families of Schizophrenia Patients With Different Familial Loadings. Schizophrenia Bulletin, 2013, 39, 537-546.	4.3	27
29	Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109868.	4.8	27
30	Identification of novel loci for bipolar I disorder in a multi-stage genome-wide association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 58-64.	4.8	26
31	P50-N100-P200 sensory gating deficits in adolescents and young adults with autism spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109683.	4.8	26
32	ANXA7, PPP3CB, DNAJC9, and ZMYND17 Genes at Chromosome 10q22 Associated with the Subgroup of Schizophrenia with Deficits in Attention and Executive Function. Biological Psychiatry, 2011, 70, 51-58.	1.3	25
33	Development of a brief self-report questionnaire for screening putative pre-psychotic states. Schizophrenia Research, 2013, 143, 32-37.	2.0	25
34	Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis. Schizophrenia Research, 2015, 164, 40-46.	2.0	25
35	Oneâ€year postâ€hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a populationâ€based study. Bipolar Disorders, 2010, 12, 859-865.	1.9	24
36	Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. Journal of the Formosan Medical Association, 2015, 114, 438-445.	1.7	24

#	Article	IF	CITATIONS
37	Mismatch Negativity and P3a in Adolescents and Young Adults with Autism Spectrum Disorders: Behavioral Correlates and Clinical Implications. Journal of Autism and Developmental Disorders, 2018, 48, 1684-1697.	2.7	24
38	Primary and secondary alterations of white matter connectivity in schizophrenia: A study on first-episode and chronic patients using whole-brain tractography-based analysis. Schizophrenia Research, 2015, 169, 54-61.	2.0	23
39	Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. Journal of Affective Disorders, 2016, 197, 189-195.	4.1	23
40	Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis. Frontiers in Psychiatry, 2019, 10, 223.	2.6	23
41	Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neuroscience Letters, 2010, 468, 330-333.	2.1	21
42	Altered integrity of the right arcuate fasciculus as a trait marker of schizophrenia: A sibling study using tractographyâ€based analysis of the whole brain. Human Brain Mapping, 2015, 36, 1065-1076.	3.6	21
43	Patterns and Clinical Correlates of Neuropsychologic Deficits in Patients with Schizophrenia. Journal of the Formosan Medical Association, 2006, 105, 978-991.	1.7	20
44	Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: Stability in the long term course. Journal of Psychiatric Research, 2006, 40, 613-621.	3.1	19
45	The multidimensionality of schizotypy in nonpsychotic relatives of patients with schizophrenia and its applications in ordered subsets linkage analysis of schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1-9.	1.7	19
46	Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia. Genes, Brain and Behavior, 2009, 8, 228-237.	2.2	19
47	Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2013, 33, 18-23.	1.4	19
48	Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study. Schizophrenia Bulletin, 2018, 44, 798-806.	4.3	19
49	Visuospatial working memory deficits in remitted patients with bipolar disorder: susceptibility to the effects of GABAergic agonists. Bipolar Disorders, 2011, 13, 365-376.	1.9	18
50	Transcriptome Changes in Relation to Manic Episode. Frontiers in Psychiatry, 2019, 10, 280.	2.6	18
51	Advanced Paternal Age and Early Onset of Schizophrenia in Sporadic Cases: Not Confounded by Parental Polygenic Risk for Schizophrenia. Biological Psychiatry, 2019, 86, 56-64.	1.3	18
52	Stable signatures of schizophrenia in the corticalâ€"subcorticalâ€"cerebellar network using fMRI of verbal working memory. Schizophrenia Research, 2013, 151, 133-140.	2.0	17
53	Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. Journal of Clinical Psychopharmacology, 2015, 35, 635-644.	1.4	17
54	Evaluation of RGS4 as a candidate gene for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 418-420.	1.7	16

#	Article	IF	CITATIONS
55	Neutropenia Associated With the Comedication of Quetiapine and Valproate in 2 Elderly Patients. Journal of Clinical Psychopharmacology, 2012, 32, 416-417.	1.4	16
56	Olanzapine-Induced Hyponatremia in a Patient with Autism. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 699-700.	1.3	16
57	No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families. Schizophrenia Research, 2007, 93, 391-398.	2.0	15
58	Comorbid prevalence of alcohol dependence, substance abuse, and external cause of injury in patients with bipolar disorder in a nationwide representative sample in Taiwan. Bipolar Disorders, 2012, 14, 677-679.	1.9	14
59	A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity. Psychiatry Research, 2014, 218, 356-358.	3.3	14
60	Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia. Human Brain Mapping, 2018, 39, 2007-2019.	3.6	14
61	Bupropion-Related Parkinsonism and Dystonia. Journal of Clinical Psychopharmacology, 2009, 29, 616-618.	1.4	13
62	More evidence to support the role of S2 in P50 studies. Schizophrenia Research, 2010, 122, 270-272.	2.0	13
63	Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan — A population-based and matched-control study. Journal of Affective Disorders, 2012, 141, 449-456.	4.1	13
64	Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up. Journal of the Formosan Medical Association, 2015, 114, 539-545.	1.7	13
65	HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention. Psychiatric Genetics, 2007, 17, 333-338.	1.1	12
66	Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database. Journal of Affective Disorders, 2017, 218, 327-334.	4.1	12
67	Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1089-1090.	4.8	11
68	Clinical alertness to valproic acid-induced hyperammonemia-two case reports. Journal of Psychopharmacology, 2010, 24, 943-945.	4.0	11
69	A case of schizophrenia with dysphagia successfully treated by a multidimensional approach. General Hospital Psychiatry, 2010, 32, 559.e11-559.e13.	2.4	10
70	Comparative effect of antipsychotics on risk of selfâ€harm among patients with schizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 296-305.	4.5	10
71	Association evidence of schizophrenia with distal genomic region of NOTCH4 in Taiwanese families. Genes, Brain and Behavior, 2007, 6, 497-502.	2.2	9
72	A Diagnostic Model Incorporating P50 Sensory Gating and Neuropsychological Tests for Schizophrenia. PLoS ONE, 2013, 8, e57197.	2. 5	9

#	Article	IF	Citations
73	Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?. BMC Psychiatry, 2020, 20, 552.	2.6	9
74	Stigmas toward psychosisâ€related clinical features among the general public in Taiwan. Asia-Pacific Psychiatry, 2020, 12, e12370.	2.2	8
75	Handedness and schizotypy in non-psychotic relatives of patients with schizophrenia. Laterality, 2011, 16, 690-706.	1.0	7
76	Effects of affective arousal on choice behavior, reward prediction errors, and feedback-related negativities in human reward-based decision making. Frontiers in Psychology, 2015, 6, 592.	2.1	7
77	Protocol of guided antipsychotic reduction to reach minimum effective dose (<scp>GARMED</scp>) in patients with remitted psychosis based on pragmatic design. Microbial Biotechnology, 2022, 16, 178-185.	1.7	7
78	Metforminâ€induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine. Psychiatry and Clinical Neurosciences, 2016, 70, 362-363.	1.8	6
79	Association between mismatch negativity and voxel-based brain volume in schizophrenia. Clinical Neurophysiology, 2018, 129, 1899-1906.	1.5	6
80	Trajectories after firstâ€episode psychosis: Complement to ambiguous outcomes of longâ€term antipsychotic treatment by exploring a few hidden cases. Microbial Biotechnology, 2019, 13, 895-901.	1.7	5
81	Social cognition in schizophrenia: A network-based approach to a Taiwanese version of the Reading the Mind in the Eyes test. Journal of the Formosan Medical Association, 2020, 119, 439-448.	1.7	5
82	Genetic associations and expression of extra-short isoforms of disrupted-in-schizophrenia 1 in a neurocognitive subgroup of schizophrenia. Journal of Human Genetics, 2019, 64, 653-663.	2.3	4
83	Mismatch negativity and P3a in drug-naive adults with attention-deficit hyperactivity disorder. Psychological Medicine, 2021, , 1-11.	4.5	4
84	Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis. Frontiers in Psychiatry, 2021, 12, 714878.	2.6	4
85	Dual-modality impairment of implicit learning of letter-strings versus color-patterns in patients with schizophrenia. Behavioral and Brain Functions, 2005, $1,23$.	3.3	3
86	Acoustic Neuroma Identified After Electroconvulsive Therapy in a Patient With Recurrent Major Depression and Undifferentiated Somatoform Disorder. Journal of ECT, 2010, 26, 330-331.	0.6	3
87	Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode. Journal of the Formosan Medical Association, 2012, 111, 265-274.	1.7	3
88	Zotepine-related myopathy in a patient with schizophrenia. European Journal of Clinical Pharmacology, 2013, 69, 725-726.	1.9	3
89	The tridimensional personality of male heroin users treated with methadone in Taiwan. Comprehensive Psychiatry, 2014, 55, 1220-1226.	3.1	3
90	Clinical characteristics and outcomes associated with weekend admissions to psychiatric wards in Taiwan. General Hospital Psychiatry, 2019, 60, 20-26.	2.4	3

#	Article	IF	CITATIONS
91	Sex as a Moderating Factor in the Relationship Between Hippocampal Volume and Sensory Gating in Patients With Schizophrenia. Clinical EEG and Neuroscience, 2019, 50, 227-230.	1.7	3
92	The experiences of family resilience from the view of the adult children of parents with bipolar disorder in Chinese society. Journal of Advanced Nursing, 2021, 78, 176.	3.3	3
93	Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia. Journal of Personalized Medicine, 2021, 11, 1198.	2.5	3
94	Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists' Attitudes in Taiwan. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 465-475.	2.2	3
95	Misfortune may be a blessing in disguise: Fairness perception and emotion modulate decision making. Psychophysiology, 2017, 54, 1163-1179.	2.4	2
96	Points that need attention in auditory N100 gating research in schizophrenia. Clinical Neurophysiology, 2019, 130, 196.	1.5	2
97	A quarter of century after: The changing ecology of psychiatric emergency services. Asia-Pacific Psychiatry, 2022, 14, e12487.	2.2	2
98	Follow-up of subjects labelled with putative pre-psychotic states: Viewed from a transdiagnostic clinical high-at-risk mental state (CHARMS) paradigm. Journal of the Formosan Medical Association, 2022, 121, 1159-1166.	1.7	2
99	Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship. NPJ Schizophrenia, 2022, 8, .	3.6	2
100	Dysregulated affective arousal regulates reward-based decision making in patients with schizophrenia: an integrated study. NPJ Schizophrenia, 2022, 8, 26.	3.6	1
101	Impairment of color-pattern implicit learning and P50 AEP gating in schizophrenic patients: A 3D brain mapping study. NeuroImage, 2001, 13, 1037.	4.2	O
102	TIME-FREQUENCY ANALYSIS OF MISMATCH NEGATIVITY IN SCHIZOPHRENIA PATIENTS IN TAIWAN. Biomedical Engineering - Applications, Basis and Communications, 2011, 23, 287-293.	0.6	0
103	Poster #S38 LANGUAGE-RELATED LATERALIZATION BEFORE AND AFTER ANTIPSYCHOTIC TREATMENT IN PRODROMAL OR FIRST-EPISODE PSYCHOSIS: AN FMRI STUDY. Schizophrenia Research, 2014, 153, S102.	2.0	0
104	Utilization of inpatient electroconvulsive therapy in an academic medical center in Taiwan. Brain Stimulation, 2015, 8, 430-431.	1.6	0
105	T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S186-S187.	4.3	O
106	T81POLYGENIC RISK FOR SCHIZOPHRENIA AND SCHIZOTYPAL PERSONALITY IN NONPSYCHOTIC RELATIVES FROM MULTIPLEX FAMILIES WITH SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S259.	0.7	0
107	Points that need attention in quantitative EEG gamma synchronization. Journal of Affective Disorders, 2019, 255, 177-178.	4.1	O
108	S122. TEN-YEAR FOLLOW-UP AFTER FIRST EPISODE PSYCHOSIS: FOCUSED ON LOW DOSE ANTIPSYCHOTIC MAINTENANCE AND FUNCTIONING. Schizophrenia Bulletin, 2020, 46, S82-S82.	4.3	0

#	Article	IF	CITATIONS
109	Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532110643.	2.7	O